CDKN2B-AS1 and atherosclerosis: In summary, we identify a novel mechanism by which metformin via lncRNA-ANRIL pathway limits VSMC phenotypic switching, resulting in the suppression of atherosclerosis lesion (Supplementary Figure 3).